Abbott Laboratories has agreed to pay at least $450 million for international rights to develop and commercialize Reata Pharmaceuticals Inc.’s experimental chronic kidney-disease drug bardoxolone. Get the full story »
Inside these posts: Kidney disease
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
